Processa Announces $200M Private Placement And Acquisition Of Vidya Therapeutics BTK Inhibitor VT-7208; Existing Shareholders To Own About 0.9% Fully Diluted
Share
Why It Matters
Processa is raising $200 million by selling new company shares to investors, and buying a medicine called VT-7208 from another company. This means the company is growing but existing owners will own a smaller piece of it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.